# BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors

> **NCT00095459** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 57 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Bevacizumab
- **DRUG:** BAY 43-9006

## Key facts

- **NCT ID:** NCT00095459
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-11-02
- **Primary completion:** 2005-11-01
- **Final completion:** 2012-07-20
- **Target enrollment:** 57 (ACTUAL)
- **Last updated:** 2019-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00095459

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00095459, "BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00095459. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*